Autoimmunization to epidermal growth factor, a component of the immunological homunculus.
Epidermal growth factor (EGF) is being tried as a vaccine in cancer immunotherapy with the aim of inducing neutralizing antibodies that might affect EGF-dependent tumors. Here we summarize our experience using the EGF self-molecule as an autoimmunigen. We report here that IgG anti-EGF antibodies are prevalent in healthy people and that augmentation of the response to EGF requires conjugation to an effective carrier and an adjuvant. Paradoxically, the response to EGF immunization could be enhanced by an 'immunosuppressive' treatment with cyclophosphamide, most probably by suppressing active control mechanisms. EGF is expressed in the thymus. Thus, EGF may be added to the immunological homunculus, the class of self-antigens to which there is both natural autoimmunity and natural regulation of the autoimmunity. The results using EGF as a vaccine can teach us about the homunculus and how to activate it.
Gonzalez
G
G
Center of Molecular Immunology, P.O.Box: 16040, Havana 11600, Cuba.
Montero
E
E
Leon
K
K
Cohen
I R
IR
Lage
A
A
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D015551:Autoimmunity; D019496:Cancer Vaccines / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D016056:Immunodominant Epitopes; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D019496:Cancer Vaccines; D016056:Immunodominant Epitopes; D007166:Immunosuppressive Agents; D004815:Epidermal Growth Factor; D003520:Cyclophosphamide